1. 124PAssociation of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306). (23rd October 2018) Authors: Miller-Phillips, L; Fischer von Weikersthal, L; Kaiser, F; Al-Batran, S-E; Heintges, T; Neureiter, D; Kahl, C; Kullmann, F; Moehler, M; Scheithauer, W; Vazart, C; Fontaine, K; Held, S; Modest, D P; Neumann, J; Jung, A; Kirchner, T; Heinemann, V; Stintzing, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 483PA biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3. (23rd October 2018) Authors: Sunakawa, Y; Stintzing, S; Cao, S; Luecke, J; Thompson, D; Moran, M; Astrow, S H; Hsiang, J; Stephens, C; Zhang, W; Tsuji, A; Takahashi, T; Denda, T; Shimada, K; Kochi, M; Takeuchi, M; Fujii, M; Ichikawa, W; Heinemann, V; Lenz, H-J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 61PDGenetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3. (23rd October 2018) Authors: Berger, M D; Stintzing, S; Heinemann, V; Cao, S; Yang, D; Miyamoto, Y; Suenaga, M; Hanna, D L; Soni, S; Puccini, A; Tokunaga, R; Naseem, M; Battaglin, F; McSkane, M; Zhang, W; Lenz, H-J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. (14th November 2019) Authors: Stintzing, S; Wirapati, P; Lenz, H -J; Neureiter, D; Fischer von Weikersthal, L; Decker, T; Kiani, A; Kaiser, F; Al-Batran, S; Heintges, T; Lerchenmüller, C; Kahl, C; Seipelt, G; Kullmann, F; Moehler, M; Scheithauer, W; Held, S; Modest, D P; Jung, A; Kirchner, T Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1796 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PD-020Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study. (20th June 2018) Authors: Modest, D; von Weikersthal, L Fischer; Decker, T; Vehling-Kaiser, U; Uhlig, J; Schenk, M; Freiberg-Richter, J; Peuser, B; Denzlinger, C; Reddemann, C Peveling genannt; Graeven, U; Schuch, G; Schwaner, I; Stahler, A; Jung, A; Kirchner, T; Held, S; Stintzing, S; Giessen-Jung, C; Heinemann, V Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗